STAT3 and plasma cell myeloma: Ruxolitinib upregulates CD38 expression via inhibition of STAT3 phosphorylation, thus enhances the DARA-mediated antibody-dependent cellular cytotoxicity (ADCC) against MM cell lines and primary CD138+ myeloma cells derived from MM patients [44].